曲妥珠单抗联合长春瑞滨或吉西他滨对人类表皮生长因子受体2阳性乳腺癌患者的临床观察

Clinical investigation of trastuzumab combined with different chemotherapy drugs in treatment of HER-2 positive breast cancer

目的探讨曲妥珠单抗联合长春瑞滨或吉西他滨对人类表皮生长因子受体2(HER-2)阳性乳腺癌患者的临床研究。方法选择2012年1月—2015年12月汉中市三二〇一医院收治的103例HER-2阳性乳腺癌患者,根据随机数字表法,分为A组(49例)及B组(54例),A组给予曲妥珠单抗联合长春瑞滨,B组给予曲妥珠单抗联合吉西他滨,21 d为1个疗程,共用4～6个疗程。观察两组的实体瘤疗效、健康生存质量、治疗后1、2年生存率、总生存时间、无进展生存时间及毒副反应。结果 A组部分缓解率及客观有效率明显高于B组,差异有统计学意义(P<0.05);两组完全缓急、疾病稳定及病情进展对比无统计学意义。A组的健康生存质量评分明显高于B组,差异有统计学意义(P<0.05)。A组治疗后1、2年的生存率高于B组,A组的总生存期及无进展生存时间长于B组,但差异无统计学意义。两组毒副反应对比无统计学意义。结论与吉西他滨联合曲妥珠单抗对比,长春瑞滨联合曲妥珠单抗治疗HER-2阳性乳腺癌患者的部分缓解率、客观有效率及健康生存质量较高,且毒副反应患者可耐受,值得临床推广应用。

Objective To investigate the clinical investigation of trastuzumab combined with different chemotherapy drugs in treatment of HER-2 positive breast cancer.Methods 103 cases with HER-2 positive breast cancer were divided into A group(49 cases)and B group(54 cases)according to random number table method,A group were given vinorelbine and trastuzumab,B group were given gemcitabine and trastuzumab,the solid tumor efficacy,healthy quality of life,survival rates after treatment for 1 and 2 year,total survival time,progression-free survival time and toxic side effects of two groups were observed.Results The partial remission rate and objective efficiency of A group were higher than B group(P<0.05),the complete urgency,disease stability,and disease progression of two groups had no significant difference;the healthy living quality of A group was higher than B group(P<0.05).The survival rates after treatment for 1 and 2 year of A group was higher than B group,the overall survival,progression-free survival and toxic side effects of two groups had no significant difference.Conclusion Compared with gemcitabine and trastuzumab,the vinorelbine and trastuzumab had higher partial remission rate,objective efficiency and healthy quality of life,and the toxic side effects could be tolerated,which could be worth of clinical promotion.